Suchergebnisse - "Talamonti, Marina"

PubPharm (20)

1

Tildrakizumab : the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden

enthalten in: Expert opinion on biological therapy | 2024

von Dapavo, P. | Burlando, M. | Guarneri, C. | +4

2

Tildrakizumab in moderate-to-severe plaque psoriasis : A multicenter, retrospective, real-life study

enthalten in: Dermatologic therapy | 2022

von Caldarola, G. | Galluzzo, M. | Bernardini, N. | +12

3

Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy

enthalten in: Dermatitis : contact, atopic, occupational, drug | 2022

von Chiricozzi, A. | Di Nardo, L. | Talamonti, M. | +40

4

Secukinumab for the treatment of palmoplantar psoriasis : a 2-year, multicenter, real-life observational study

enthalten in: Expert opinion on biological therapy | 2022

von Galluzzo, M. | Talamonti, M. | Atzori, L. | +12

5

Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis : A Multicenter Real-Life Observational Study

enthalten in: American journal of clinical dermatology | 2021

von Patruno, C. | Fabbrocini, G. | Longo, G. | +35

6

Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis : A Post hoc Analysis of the SUPREME Study

enthalten in: Acta dermato-venereologica | 2021

von Talamonti, M. | Malara, G. | Natalini, Y. | +22

7

Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis : a review of clinical studies

enthalten in: Expert opinion on biological therapy | 2021

von Galluzzo, M. | Talamonti, M. | Manfreda, V. | +5

8

Guselkumab : an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis

enthalten in: European journal of dermatology : EJD | 2021

von Chiricozzi, A. | Costanzo, A. | Fargnoli, M. | +21

9

Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era

enthalten in: Expert opinion on biological therapy | 2020

von Galluzzo, M. | Tofani, L. | Bianchi, L. | +1

10

In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis

enthalten in: Expert opinion on biological therapy | 2020

von Galluzzo, M. | D'Adamio, S. | Silvaggio, D. | +3